Cargando…

Phosphaturic mesenchymal tumor: Case report

Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Adam L., Richardson, Olivia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818391/
https://www.ncbi.nlm.nih.gov/pubmed/31681451
http://dx.doi.org/10.1016/j.radcr.2019.09.027
_version_ 1783463603528007680
author Richardson, Adam L.
Richardson, Olivia K.
author_facet Richardson, Adam L.
Richardson, Olivia K.
author_sort Richardson, Adam L.
collection PubMed
description Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including progressive bone pain, myopathies, arthralgias, fractures, and generalized weakness. This case report identifies a very characteristic presentation of a 37-year old African American male suffering from a PMT; with symptom onset presenting over 5-years prior to presentation with a consistent complaint of progressive and debilitating quadriparesis. The tumor was first identified by pelvic computerized tomography, although it was initially thought to be a noncontributory benign soft tissue mass. It was only after being hospitalized due to a severe and unresponsive hypophosphatemic state (less than 1 mg/dl) that the collective differential switched to one of a PMT with follow up nuclear 99mTc bone scintigraphy and magnetic resonance imaging being used to aid in the overall assessment of changes, extent, and general metabolic properties of the tumor. The confirmatory diagnosis of a PMT was later established through both serum fibroblast growth factor 23 testing and histopathologic review of the surgically removed specimen. By including this rare but curative disease into the differential of osteomalacia and thereby further examining patient serum phosphate levels, the previous 5-7 year delay in diagnosis will be dramatically reduced.
format Online
Article
Text
id pubmed-6818391
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68183912019-11-01 Phosphaturic mesenchymal tumor: Case report Richardson, Adam L. Richardson, Olivia K. Radiol Case Rep Diagnostic Imaging Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including progressive bone pain, myopathies, arthralgias, fractures, and generalized weakness. This case report identifies a very characteristic presentation of a 37-year old African American male suffering from a PMT; with symptom onset presenting over 5-years prior to presentation with a consistent complaint of progressive and debilitating quadriparesis. The tumor was first identified by pelvic computerized tomography, although it was initially thought to be a noncontributory benign soft tissue mass. It was only after being hospitalized due to a severe and unresponsive hypophosphatemic state (less than 1 mg/dl) that the collective differential switched to one of a PMT with follow up nuclear 99mTc bone scintigraphy and magnetic resonance imaging being used to aid in the overall assessment of changes, extent, and general metabolic properties of the tumor. The confirmatory diagnosis of a PMT was later established through both serum fibroblast growth factor 23 testing and histopathologic review of the surgically removed specimen. By including this rare but curative disease into the differential of osteomalacia and thereby further examining patient serum phosphate levels, the previous 5-7 year delay in diagnosis will be dramatically reduced. Elsevier 2019-10-22 /pmc/articles/PMC6818391/ /pubmed/31681451 http://dx.doi.org/10.1016/j.radcr.2019.09.027 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Diagnostic Imaging
Richardson, Adam L.
Richardson, Olivia K.
Phosphaturic mesenchymal tumor: Case report
title Phosphaturic mesenchymal tumor: Case report
title_full Phosphaturic mesenchymal tumor: Case report
title_fullStr Phosphaturic mesenchymal tumor: Case report
title_full_unstemmed Phosphaturic mesenchymal tumor: Case report
title_short Phosphaturic mesenchymal tumor: Case report
title_sort phosphaturic mesenchymal tumor: case report
topic Diagnostic Imaging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818391/
https://www.ncbi.nlm.nih.gov/pubmed/31681451
http://dx.doi.org/10.1016/j.radcr.2019.09.027
work_keys_str_mv AT richardsonadaml phosphaturicmesenchymaltumorcasereport
AT richardsonoliviak phosphaturicmesenchymaltumorcasereport